BUENA, N.J., Feb. 16, 2021 /PRNewswire/ -- Teligent, Inc.
(Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic
pharmaceutical company, today announced it has appointed industry
veteran William S. Marth to its
Board of Directors, effective immediately. Mr. Marth brings over 25
years of expertise and a proven track record of leading companies
in the generic pharmaceutical and contract manufacturing
industries.
John Celentano, Chairman of
Teligent's Board of Directors, commented on the appointment,
stating that "We are excited to have Bill join Teligent's Board of
Directors. He is a strategic leader with extensive experience in
helping businesses transform and achieve their potential. Following
the strategic steps we announced earlier this year to strengthen
the Company's balance sheet and position the business for success,
we have reached a critical time in Teligent's journey where Bill's
innovative thinking will be invaluable. We are confident that the
appointment of Bill, along with the existing members of our Board,
will help ensure that Teligent has strong Board leadership as the
company works to execute on its strategic plans going forward."
Mr. Marth currently serves as the Managing Partner of North
Ocean Ventures, LLC, a consulting firm that helps pharmaceutical
businesses realize their full potential, and most recently served
as the Global President and Chief Executive Officer of North America & Europe of Avet Pharma Holdings Inc., a
specialty generic pharmaceutical company and subsidiary of Emcure
Pharmaceuticals Ltd. Previously, Mr. Marth served as the President
and CEO of Albany Molecular Research, Inc. (AMRI), a global
contract research and manufacturing company providing services to
the pharmaceutical and biotechnology industries. Before that, Mr.
Marth served in various senior leadership roles at Teva
Pharmaceutical Industries Limited, including President and CEO of
Teva Pharmaceuticals – Americas, as well as CEO of Teva North America and CEO of Teva USA, while also serving as a member of Teva's
global executive management team.
Notably, after a series of seven acquisitions in four years Mr.
Marth built AMRI into one of the top five global contract
development and manufacturing organizations with revenues in
excess of $700 million, after which
Mr. Marth led the take-private of AMRI in September of 2017 in a
$1.6 billion transaction.
Additionally, Mr. Marth played a critical role in the expansion of
Teva Pharmaceuticals in the Americas from 1999 – 2012.
Mr. Marth said, "I am pleased to join Teligent's Board of
Directors at this exciting time of revitalization and potential
growth for the Company. Teligent's products and reputation as a
quality manufacturer are known throughout the industry, and I am
looking forward to working with management and the Board to grow
Teligent's business and maximize the Company's position in the
generic pharmaceutical, product development and contract
manufacturing marketplaces."
Mr. Marth holds a Bachelor of Science in Pharmacy from the
University of Illinois College of
Pharmacy, a Master's in Business Administration from the
Keller Graduate School of Management, DeVry
University, and an honorary Doctor of Humane Letters from
the Albany College of Pharmacy and
Health Sciences.
About Teligent, Inc.
Teligent is a New Jersey based
company focused on the development, manufacturing and marketing of
specialty generic pharmaceutical products for the United States and Canadian markets. Our
mission is to be a leading player in the specialty generic
prescription drug market. Learn more on our website
www.teligent.com.
Forward-Looking Statements and Information
This press release includes "forward-looking statements" that
are intended to qualify for the safe harbors from liability
provided by Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements other than statements of historical facts are
statements that could be deemed forward-looking. These statements
are based on current expectations, estimates, forecasts and
projections about the Company's business and the industry in which
the Company operates and the beliefs and assumptions of the
Company's management. Forward-looking statements can be identified
by the use of words such as "will," "may," "could," "should,"
"would," "believe," "depends," "expect," "goal," "anticipate,"
"forecast," "project," "future," "intend," "plan," "estimate,"
"target," "indicate," "outlook," and similar expressions of future
intent or the negative of such terms. Forward-looking statements
are neither historical facts nor assurances of future performance.
Instead, these forward-looking statements are based on management's
current beliefs, expectations and assumptions and are subject to
risks and uncertainties. These statements are based on the
Company's current beliefs or expectations and are inherently
subject to various risks and uncertainties, including those set
forth under the caption "Risk Factors" in the prospectus supplement
relating to the Company's current At the Market offering and the
Company's most recent Annual Report on Form 10-K, Quarterly Reports
on Form 10-Q and other periodic reports the Company files with the
Securities and Exchange Commission. Additionally, many of these
risks and uncertainties are currently amplified by and will
continue to be amplified by, or in the future may be amplified by,
the COVID-19 outbreak and the effects thereof on the Company's
future performance and results of operations. It is not possible to
predict or identify all such risks. There may be additional risks
that the Company considers immaterial or which are unknown. You
should not rely upon forward-looking statements as predictions of
future events. The forward-looking statements included in
this press release speak only as of the date hereof and, subject to
any continuing obligations under applicable law or any relevant
stock exchange rules, we expressly disclaim any obligation to
disseminate, after the date of this document, any updates or
revisions to any such forward-looking statements to reflect any
change in expectations or events, conditions or circumstances on
which any such statements are based.
Media:
Rachel Chesley /
Sarah Rosselet
TeligentCommunications@fticonsulting.com
Investors:
InvestorRelations@Teligent.com
View original
content:http://www.prnewswire.com/news-releases/teligent-inc-announces-appointment-of-william-s-marth-to-board-of-directors-301228555.html
SOURCE Teligent, Inc.